Financial Statements

Krystal Biotech, Inc. (KRYS)

$125.76

+1.56 (+1.26%)
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers are in thousands , Years are calendar years not fiscal years

Retained Earning Schedule

Year 2022 2021 2020 2019 2018
Retained Earnings (Previous Year) -141-71-39-20-
Net Income -140-70-32-19-11
Stock Dividends -----9
Dividend Paid -----
Retained Earnings -281-141-71-39-20

PPE Schedule

Year 2022 2021 2020 2019 2018
Gross PPE 12034113-
Annual Depreciation 10315438155
Capital Expenditure -53-68-15-6-2
Net PPE 17012034113

Intangible and Goodwill Schedule

Year 2022 2021 2020 2019 2018
Intangible and Goodwill (Previous Year) -----
New Purchases -8-9-3-190-319
Intangible and Goodwill -----

Krystal Biotech, Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Krystal Biotech, Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.